Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119982 | 0.86 | USP30 (0.41) | DGAT1USP30MAPTHRH3FFAR1 | |
| SCHEMBL30376628 | 0.86 | USP30 (0.41) | DGAT1USP30MAPTHRH3FFAR1 | |
| SCHEMBL9946217 | 0.85 | MAPT (0.51) | DGAT1USP30MAPTHRH3LPL | |
| SCHEMBL1838991 | 0.84 | MAPK8 (0.41) | PDE10ADGAT1USP30MAPK8MAPK10 | |
| SCHEMBL10325539 | 0.82 | DGAT1 (0.46) | DGAT1USP30DEGS1HRH3 | |
| SCHEMBL29378036 | 0.82 | MAPT (0.44) | DGAT1USP30MAPTLPLLIPG | |
| SCHEMBL2068884 | 0.82 | MAPT (0.41) | DGAT1USP30MAPTLPLLIPG | |
| SCHEMBL1484906 | 0.82 | MAPT (0.44) | DGAT1USP30MAPTLPLLIPG | |
| SCHEMBL20839928 | 0.81 | MCHR1 (0.38) | DGAT1USP30MAPT | |
| SCHEMBL30609386 | 0.81 | USP30 (0.42) | PDE10ADGAT1USP30MAPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604023-B2 | 1,4-benzodiazepinone compounds and their use in treating cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010121164-A2 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010121164-A2 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | HTR4, HTR1A, HTR3B | PDE10A 2146/4885DGAT1 3980/4885USP30 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.